Seres Therapeutics, Inc.
Cash Flow History
| Period | Operating Cash Flow | Free Cash Flow | CapEx | Share-Based Compensation |
|---|---|---|---|---|
| Mar 2021 | $-29.5M | $-30.8M | $1.3M | $3.6M |
| Jun 2021 | $-39.7M | $-42.2M | $2.6M | — |
| Sep 2021 | $127.7M | $123.7M | $4.1M | — |
| Mar 2022 | $-66.4M | $-69.4M | $3.0M | $5.1M |
| Jun 2022 | $-49.9M | $-52.1M | $2.2M | — |
| Sep 2022 | $-59.6M | $-60.8M | $1.2M | — |
| Mar 2023 | $-76.6M | $-80.7M | $4.1M | $6.9M |
| Jun 2023 | $66.0M | $64.8M | $1.2M | — |
| Sep 2023 | $-59.3M | $-61.1M | $1.8M | — |
| Mar 2024 | $-35.2M | $-35.3M | $62.0K | $6.5M |
| Jun 2024 | $-39.8M | $-39.9M | $99.0K | — |
| Sep 2024 | $-34.7M | $-34.8M | $129.0K | — |
| Mar 2025 | $26.9M | $26.9M | $34.0K | $2.8M |
| Jun 2025 | $-13.3M | $-13.5M | $181.0K | — |
| Sep 2025 | $2.2M | $2.2M | $8.0K | — |